Bolt Biotherapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $6.83M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | After market close | $5.00K | $-4.57 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | $26.00K | $-4.31 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | $2.50M | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $2.20M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $1.80M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | After market close | $1.20M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | $1.10M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | $1.30M | $-0.56 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | After market close | – | – | – |
Press releases
Announcements Bolt Biotherapeutics filed with the SEC
Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
Results of operations · Regulation FD disclosure · EX-99#2 to Form 8-K
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K
Bolt Biotherapeutics Reports Interim BDC-1001 Phase 1/2 Data Demonstrating a Safe and Well-tolerated Profile and Emerging Clinical Activity at the ESMO Immuno-Oncology Congress 2021
Regulation FD disclosure · EX-99.1 to Form 8-K
December 2021 1 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
Results of operations · EX-99.1 to Form 8-K